97 results about "Drug resource" patented technology

The invention provides an amoxicillin / clavulanate (8:1) tablet and a preparation method thereof. The amoxicillin / clavulanate (8:1) tablet has the advantages of simple preparation process, good quality controllability and stability and low forming-production cost by adopting the mixed amoxicillin / clavulanate (8:1) intermediate materials having good quality controllability and stability as the main drug resource.

The invention relates to a method for increasing the contents of tanshinone and salvianolic acid in a salvia miltiorrhiza hairy root by using a transgene AtMYC2, belonging to the technical field of gene engineering. The method comprises the steps of constructing a high-efficiency expression vector of a plant by using an arabidopsis transcription factor AtMYC2, and carrying out genetic transformation on salvia miltiorrhiza leaves to obtain a gene AtMYC2 overexpressed transgenetic salvia miltiorrhiza hairy root; analyzing the expression of AtMYC2 in the transgenetic salvia miltiorrhiza hairy root and related genes in biosynthetic pathways of tanshinone and salvianolic acid through qRT-PCR; measuring the contents of tanshinone and salvianolic acid in the transgenetic salvia miltiorrhiza hairy root by using a high-performance liquid chromatography (HPLC); and measuring the antioxidant activity of tanshinone and salvianolic acid in the transgenetic salvia miltiorrhiza hairy root by using a DPPH free radical scavenging method. The invention provides the method for simultaneously increasing the contents of tanshinone and salvianolic acid in salvia miltiorrhiza hairy root and also provides a novel high-quality raw material for producing tanshinone and salvianolic acid with important clinic demands so as to have the positive promoting significance and application value for relieving the problem that the drug resources of tanshinone and salvianolic acid are short.

The invention discloses total oligose in cistanche deserticola and a preparation method and application thereof. In the total oligose in cistanche deserticola of the invention, the content of the contained total oligose is not less than 40 to 60 percent based on glucose (C6H12O6), and the content of galactitol (C6H1>O6) contained in the total oligose ranges from 0.0 to 25.0 percent. Used as drugs for relaxing bowel, the total oligose in cistanche deserticola of the invention eliminates the complex purification process required by purifying the galactitol from the cistanche deserticola, leads to maximum utilization of drug resources of cistanche deserticola and enhances the drug effect, thus having the advantages of definite healing efficacy, few side-effects and large group of application people. Due to moderate bowel-relaxing effect, the total oligose in cistanche deserticola is especially suitable for the old, lying-in women or valetudinarians.

The invention provides a method for increasing content of tanshinone in salvia miltiorrhiza bunge hairy roots. According to the method, recombinant plant expression vectors are constructed with salvia miltiorrhiza bunge SmWRKY70 transcription factors, and SmWRKY70 gene modified salvia miltiorrhiza bunge hairy roots are obtained through genetic transformation of salvia miltiorrhiza bunge leaves. According to the method, 789 bp of a coding frame sequence of the SmWRKY70 transcription factors is isolated and cloned from salvia miltiorrhiza bunge, and 918 bp of a promoter sequence of the SmWRKY70 transcription factors is cloned; subcellular localization vectors of the SmWRKY70 transcription factors are constructed; overexpression vectors of SmWRKY70 genes are constructed, and overexpression salvia miltiorrhiza bunge hairy roots with the SmWRKY70 genes are obtained through genetic transformation of the salvia miltiorrhiza bunge leaves. The content of the tanshinone in the gene modified salvia miltiorrhiza bunge hairy roots obtained with the method is significantly increased, a novel high-quality drug resource is provided for production of the tanshinone with important clinical demands, and the active promotion effect on alleviating shortage of the tanshinone drug resource is realized, and the method has the important theoretical significance and the potential application value.

The invention discloses marine traditional Chinese medicine gracilariopsis lemaneiformis polysaccharide derived from red alga plant gracilariopsis lemaneiformis, discloses a synergistic effect of the gracilariopsis lemaneiformis polysaccharide serving as anti-tumor drugs, especially a synergist of cis-platinum for the first time, and further discloses an application of the gracilariopsis lemaneiformis polysaccharide to preparation of drugs or healthcare products or food for treating tumors. The gracilariopsis lemaneiformis polysaccharide can serve as a synergist of the anti-tumor drugs. The anti-tumor effect is achieved mainly by retraining growth and propagation of tumor cells, and the anti-tumor effect is achieved for gastric adenocarcinoma, lung cancer and carcinoma of the uterine cervix. The invention further discloses a preparation method of the gracilariopsis lemaneiformis polysaccharide and a detection method of the anti-tumor effect of the gracilariopsis lemaneiformis polysaccharide. A new way is provided for further utilization of gracilariopsis lemaneiformis serving as marine drug resources, and a new choice is provided for development of the anti-tumor drugs for treating or preventing tumors through the application of the gracilariopsis lemaneiformis polysaccharide to preparation of the anti-tumor drugs or anti-cancer healthcare products or food.

The invention relates to a novel application of a traditional Chinese medicinal composition in the preparation of a medicament for controlling diabetes complications. The prescription contains, by weight, 100 parts of red ginseng, 250 parts of epimeddium, 750 parts of brine-heated Psoralea corylifolia, 250 parts of wolfberry, 250 parts of ephedra stem, 50 parts of Asarum Herb, 375 parts of red sage root and 250 parts of leech. The dosage form comprises pills, a particulate agent, hard capsules, soft capsules, tablets, dropping pills or an oral liquid. The invention aims to provide a novel treatment application of the pharmaceutical composition, enlarge the clinic application range of the pharmaceutical composition and avoid waste of good drug resources.

The invention relates to a bone injury ointment for external use, which is applied to treating human body bone fractures and parenchyma contuses and sprains. The bone injury ointment is prepared from drug loose powder added with honey according to a weight ratio of 1:1.7-2.0, wherein the drug loose powder and the honey are mixed evenly, and the drug powder is prepared by evenly mixing the following components in portion by weight: 8 to 11 portions of radix angelicae powder, 3 to 7 portions of rhubarb powder, 8 to 11 portions of gardenia powder, 3 to 7 portions of frankincense powder, 3 to 7 portions of radix paeoniae rubra powder, and 3 to 7 portions of safflower powder. The bone injury ointment has the advantages of flexible drug application, more convenient examination and observation of state of illness, simple and convenient dressing change to reduce replacement risk, quick pain alleviation, detumescence and callus growth, greatly reduced pains for patients, wide range of drug resources, and the like.

The invention belongs to the technical field of biological medicine, relates to a method for preparing ginsenoside Rd by utilizing microbial conversion and in particular relates to a microbial conversion method for preparing the ginsenoside Rd by fermenting and converting aspergillus niger into various glycol-type ginsenosides. In the method disclosed by the invention, a high-conversion industrial aspergillus niger strain with culture preservation number being CICC40426 is adopted, various glycol-type ginsenosides are obtained by fermentation and conversion in a full-automatic fermentation tank, and high-purity ginsenoside Rd is prepared through purification and crystallization by virtue of macroporous resin. The method disclosed by the invention is simple in process, low in cost and high in yield and is environment-friendly; and with adoption of the method disclosed by the invention, industrial preparation of the ginsenoside Rd can be realized, source of the ginsenoside Rd drug resource is expanded, and wide medical care market demand is met, so that the method disclosed by the invention has great value.

The invention belongs to the field of biological engineering, and particularly relates to a method for improving the content of betulin and oleanolic acid in a birch cell by utilizing MeJA (methyl-jasmonate) and SA (salicyl acid), which comprises the following steps of: inoculating a birch tissure culture seedling stem to NT + 0.1 mg / L of 6-BA and 0.01 mg / L of TDZ culture mediums to induce birch callus, and obtaining a birch suspension cell with high content of total triterpenes through multi-time subculture, screening and suspension culture; inoculating the screened cell into the same liquid culture medium, wherein the inoculation amount is 3g / 100ml; adding 100mu Mum / L of MeJA and 50mg / L of SA when the shake culture is performed at the seventh day; after 24-48h, obtaining the product; and detecting the content of total triterpenes, betulin and oleanolic acid in the cell. Through the comparison of the two kinds of processing methods, the content of total triterpenes is improved by 21.6-31.7%, the content of oleanolic acid is improved by 277.4-369.34%, and the content of betulin is improved by 44.42-179.58%. The application of the invention provides a new path for solving the problem of shortage of natural plant drug resources and realizing large-scale industrial production of betulin and oleanolic acid drugs.

The invention discloses an artemisia apiacea WRKY type transcription factor coding sequence. The coding sequence is marked as AaGSW2, the nucleotide sequence is shown by SEQ ID NO:1, and the amino acid sequence is shown by SEQ ID NO:2. According to the coded WRKY type transcription factor AaGSW2 disclosed by the invention, the artemisinin content is increased by controlling the expression of artemisinin synthesis key enzyme gene. The artemisinin content in the blades of non-transgenic common artemisia apiacea is 9mg / g DW, and the blade artemisinin content of the transgenic artemisia apiacea expressed by the over-expression AaGSW2 gene is increased to 21mg / g DW. The invention is of great significance in providing a high-yield and stable new drug resource for large-scale production of artemisinin.

The invention discloses Artemisia annua L. PDR sub-family transport protein. Amino acid sequences of the protein comprise the amino acid sequence shown as SEQ ID NO:2 or the amino acid sequence of the protein is shown as SEQ ID NO:2 or nucleic acid codes crossed by the protein and complementary chains of nucleic acid of protein with the coded amino acid sequence shown in SEQ ID NO:2 under the highly-strict condition are achieved. Furthermore, the protein is named AaPDR1 by the inventor and is transport protein specifically expressed by Artemisia annua L. secreting type gladular trichomes, and it is proved through a yeast transport experiment and interference of Artemisia annua L. in the transport protein that the AaPDR1 participates in transporting an artemisinin synthetic route intermediate product dihydroartemisinic acid in Artemisia annua L.. The Artemisia annua L. PDR sub-family transport protein has great significance in providing high-yield and stable new drug resources for large-scale production of artemisinin.

The invention provides a drug information sharing method, a client and a server. The drug information sharing method comprises: obtaining a drug identifier according to a search entry, and generating a drug search request, wherein the drug search request comprises a first user identifier; sending the drug search request to a server, wherein the drug search request is used for searching drug information conforming to specified conditions in drug data stored in the server, the drug data are composed of drug information marked by more than one second user identifier, and the more than one second user identifier is associated with the first user identifier; and receiving at least one piece of drug information returned by the server according to the drug search request. The method can be used for sharing and dispatching idle drugs in various families to reasonably allocate drug resources of friends, so as to improve the user experience.

The invention discloses a method for planting fungi hexagona apiaria (CCTCC NO.M208121) sporocarp for a rare drug. The method comprises the following steps: the cultivation of a separated and purified hexagona apiaria seed, the cultivation of hypha in a fungus sack, the cultivation of the hexagona apiaria sporocarp and the harvest of the hexagona apiaria sporocarp. The planting of the hexagona apiaria sporocarp through a sack material needs about 2 to 3 months from the production of a strain, inoculation, fungus cultivation, fruiting cultivation to the harvest of the sporocarp; the method has short production period and rapid effect, realizes large-scale cultivation of the hexagona apiaria sporocarp, fundamentally solves the problem of insufficient wild resources, provides abundant drug resources for further research of the active components, the pharmacological action, a pharmaceutical mechanism and a toxicity test of the hexagona apiaria sporocarp, and lays a foundation for better developing and utilizing the hexagona apiaria.

The invention belongs to the technical field of medicines and discloses a method for extracting rosmarinic acid from labiates and a prepared drug. The method comprises the following steps: dissolving a labiate extract containing water-soluble rosmarinic acid in 0%-95% acidic alcohol-water solution, then adding medicinal macro-porous resin and washing by using 0%-20% alcohol-water solution; eluting by using 20%-95% alcohol-water solution, thereby acquiring a crude product of rosmarinic acid; filtering the crude product of rosmarinic acid by adopting an ultra-filtration membrane, thereby acquiring the rosmarinic acid; and repeatedly extracting the rosmarinic acid by using organic and inorganic solvents, concentrating, standing by, crystallizing in an acidic solvent, re-crystallizing and drying, thereby acquiring a pure product of rosmarinic acid. According to the invention, the pure product of rosmarinic acid is acquired according to the steps of passing by macro-porous resin, performing ultra-filtration, repeatedly extracting the rosmarinic acid by using organic and inorganic solvents, concentrating, standing by, crystallizing in the acidic solvent, re-crystallizing and drying. Various drug resources can be used for supplying rosmarinic acid; the technology is simple and convenient, the operation is easy and the cost is low; and the method is suitable for industrial production.

A powdered drug for treating pressure sore through external application belongs to an external western medicine preparation, which mainly solves the problem of pressure sore treatment. Raw materials for preparing effective components of the powdered drug comprise the following weight parts: 1-10 parts of sulfamethoxazole compound, 1-10 parts of metronidazole, 5-50 parts of Vitamin C, 5-50 parts of vitamin B complex, 5-50 parts of nicotinic acid, 3-15 parts of egg shell inner membrane dried by excipients. When in use, a mackintosh, a plurality of sterilized dressings and a sterilized dressing bag are padded under the part with pressure sore; the sore surface is repeatedly washed from top to bottom with 0.9 percent physiological saline extracted with a disposable sterilized syringe until the wound is clean and then is washed from top to bottom for twice to three times with 0.1 percent chlorhexidine solution; when blisters are formed, a disposable sterilized syringe is used for drawing out the liquid in the blisters; when necrotic tissues are formed, the necrotic tissues are eliminated with sterile forceps and sterile shears, then repeated washing from top to bottom with 0.1 percent chlorhexidine solution is carried out until the sore surface is clean, and then the prepared powdered drug is evenly sprinkled on the sore surface by a sterilized cotton bud; the thickness of the powdered drug is about 1mm; finally the sore surface is covered with sterilized petroleum jelly gauze and bandaged with sterilized dressing; the drug is changed once a day to prevent local compression. When new granulation tissue outgrows, the sore surface is scattered with drug powder without dressing, and the drug powder self drops off after scab is formed until the sore is healed. The powdered drug has simple and convenient preparation method, abundant drug resources, low cost, convenient and simple clinical application and remarkable effect, which is deeply welcomed by broad patients.

The invention discloses a drug which cures psoriasis and is produced by the raw materials of swamp mahogany, radix paeoniae lactiflorae, tasselblower, daphne genkwa, breynia fruticosa, erigeren candensis, eurya chinensis, garter snake, radix-polygoni multiflori, ledeboruiella root, lightyellow sophora root and Chinese atractylodes herb medicine. The drug of the invention has the advantages that: the drug has no poisonous and side effect, no stimulating effect and hypersusceptibility reaction; the function is quick; the recrudescence does not easily occur; the curing charge is low, the drug resource is wide with cheap price; the effective rate of the drug of the invention curing psoriasis is 90 percent and the curing rate is 85 percent.

The invention provides an external applying drug for curing trauma of sportsmen, which belongs to the Chinese patent drug technical field, in particular relates to a drug for curing hematoma, muscle strains, pain and old trauma caused by injuries from falls. The external applying drug can dissolve the haemostasis, promote the blood circulation, and recoverie the functions of organs. The drug dissolves the haemostasis of the injuries from falls with a success ratio approximate to 100 percent. The drug consists of giant knotweed, motherwort, rhizoma ligustici wallichii, red paeonia, ampelopsis japonica, frankincense, myrrh, safflower, peach seed, salvia miltiorrhiza, dragon blood, trumpetweed, Gardenia and wheat. The drug has low cost, wide drug resources and simple preparation technology, and is safe, reliable and nontoxic.

The invention discloses a Japan snakeroot strictosidine synthase gene, protein which is encoded by the Japan snakeroot strictosidine synthase gene and the use thereof. The Japan snakeroot strictosidine synthase gene which is provided by the invention has a nucleotide sequence or a homologous sequence which adds, replaces, inserts or losses one or a plurality of nucleotides or allele thereof and the nucleotide sequence which is derived from the Japan snakeroot strictosidine synthase gene, which are displayed in the SED ID No.1. The protein which is encoded by the gene has an amino acid sequence or the homologous sequence which adds, replaces, inserts or losses one or a plurality of amino acids, which is displayed in the SEQ ID No.2. The Japan snakeroot strictosidine synthase gene which is provided by the invention can increase the content of camptothecin which is an anticancer component in resource plants such as Japan snakeroot or camptotheca and the like through the genetic engineering technology and can be used in research and industrialization for increasing the content of the camptothecin through utilizing the transgenic technology, which is helpful for accelerating to solve the problem that the drug resources of the camptothecin are seriously scarce and has very good application prospect.

The invention discloses a liver smoothing and qi regulating drug for treating mammary gland hyperplasia and a preparation method of the liver smoothing and qi regulating drug. The liver smoothing and qi regulating drug is prepared from the following main crude drugs in parts by weight: 10-20 parts of trichosanthes kirilowii, 8-15 parts of radix asparagi, 8-15 parts of cuttlebones, 6-9 parts of cortex lycii radicis, 10-20 parts of dogwood, 8-15 parts of tangerine leaves, 6-9 parts of tangerine seeds, 5-10 parts of fructus aurantii, 5-10 parts of curculigo capitulata, 3-6 parts of motherwort fruits, 8-16 parts of concha arcae, 7-14 parts of usnea, 7-15 parts of common fenugreek seeds, 8-12 parts of rhizoma anemarrhenae, 8-16 parts of goosegrass herbs and 8-12 parts of pinellia ternata. The liver smoothing and qi regulating drug is free of side effects, safe, remarkable in curative effect, capable of treating both symptoms and root causes, cheap and available in drug resource, low in treatment cost and convenient to use, and is easily accepted by a patient; and mammary gland hyperplasia does not easily recur.

The invention discloses an antifungal pharmaceutical composition consisting of a periplaneta americana extract and an antifungal drug. The pharmaceutical composition has the antifungal effect obviously superior to that of single use of periplaneta americana and fluconazole, and has better application prospects. The antifungal pharmaceutical composition provides a new thought for development and utilization of medicinal resources of the periplaneta americana, provides a new candidate drug and therapeutic scheme for clinical treatment of vulva vaginal candidiasis, and is expected to relieve painof vast female patients. The antifungal pharmaceutical composition has great significance in reasonably and sustainably developing and utilizing the natural drug resource of periplaneta americana.

The invention provides a method of exploring a new indication of a drug. The method comprises the steps of searching, based on a drug name, drug-related molecules (genes or proteins) in a database; building an interaction network of the drug-related molecules (genes or proteins) or the drug-related molecules (genes or proteins) and first-order neighbors thereof; performing module identification on the interaction network, building a weighted or unweighted module interaction network, and performing key module identification so as to analyze functions, or directly performing function analysis of the drug-related molecules (genes or proteins) on the interaction network; and comparing a function analysis result with a known indication in a specification of the drug so as to obtain the new indication of the drug. The method uses a network pharmacology method and starts with characteristics of multiple targets and multiple paths of the drug go explore the new indication of the drug in multiple aspects such as drug-related molecules, modules and network. Compared with research of a brand-new drug, the method saves much manpower, financial and time costs, lowers the research risks, and uses existing drug resources more reasonably.

The invention discloses the application of starfishes to the preparation of a medicament for treating osteoporosis. The application of the starfishes is realized by steaming, drying, cooling and crushing Chinese medical starfish herbs, such as asterias rollestoni and asterias amurensis from asteriidae animals or Dow sun starfish from solasteridae animals, preparing and orally administrating. Proved by research, the starfishes have the functions of stimulating the growth of sclerotomal cells, promoting the pigmentation, enhancing the bone density, and the like and have remarkable effect of treating the osteoporosis. The medicament for treating osteoporosis, which is prepared by the technical scheme, has the advantages of good treatment, high effect taking, high curative effect without any side effect, and the like during clinical applications and has sufficient drug resources, simple preparation method and low cost.

The invention which belongs to the technical field of medicine relates to a new use of Esculentoside A in preparing drugs for controlling hepatic fibrosis or cirrhosis. Pharmacological experiments show that: Esculentoside A allows the generation of collagen in hepatic tissues to be substantially inhibited, the fibrosis degree to be reduced and the control effect on hepatic fibrosis and cirrhosis to be fine, so Esculentoside A can be used to prepare the drugs for controlling hepatic fibrosis or cirrhosis. The invention provides a new drug resource for controlling hepatic fibrosis or cirrhosis.

The invention discloses a method for preparing mixed amoxicillin / clavulanate materials and rapidly measuring the uniformity thereof. The purpose of uniformly mixing the amoxicillin / clavulanate materials can be achieved without forming amoxicillin / clavulanate and amoxicillin powder into granules respectively at first or adding diluting agents, such as microcrystalline cellulose and the like. The invention can provide the amoxicillin / clavulanate preparation with the main drug resource with high concentration ratio of amoxicillin / clavulanate and good quality controllability and mixing uniformity, and has the advantages of simple preparation process, good quality controllability and stability and low forming-production cost; meanwhile, the invention further provides a method for rapidly measuring the uniformity of the mixed amoxicillin / clavulanate materials, and the method, which is characterized in that the purpose of indirectly measuring the uniformity thereof can be achieved by directly measuring the water content of the mixed materials, has the advantages of high precision and repeatability.

The invention relates to a medicine for treating lumbar disc herniation, especially to a traditional Chinese medicine which is prepared from plant Chinese herbal medicines used as raw materials and is used for treating lumbar disc herniation. The traditional Chinese medicine is characterized in that Chinese herbal medicine ingredients comprise 13-19 g of Chinese angelica, 13-19 g of achyranthes root, 13-19 g of cornus officinalis, 5-15 g of poria cocos, 5-15 g of dipsacus asperoids, 5-15 g of eucommia, 13-19 g of white peony root, 6-13 g of cistanche, 3-9 g of green tangerine peel and 3-9 g of cortex acanthopanacis. Each ingredient of the traditional Chinese medicine is a natural Chinese herbal raw medicinal material. The traditional Chinese medicine has advantages of simple configuration, wide drug resource and low cost. With the efficacy of synergistic effects, the traditional Chinese medicine has effects of enriching the blood, nourishing yin, reinforcing essence and marrow, nourishing liver and kidney, managing disorder of blood system, invigorating the circulation of blood, stimulating the menstrual flow, dispersing blood stasis, strengthening the bones and muscles, dispelling wind to relieve exogenous syndrome, removing dampness to kill pain, diminishing swelling, settling pain and the like, and has a remarkable effect of treating lumbar disc herniation caused by qi-stagnancy and blood stasis, deficiency of qi and blood, liver-kidney deficiency, exogenous pathogenic factors, cold-damp arthralgia and the like.

The invention relates to a target protein for resisting cataract and the application thereof. The change rule of a crystallin beta B2 with special expression and special distribution along with the body aging process is discovered according to the phase change of the crystallin, and the crystallin is determined as the more appropriate target protein for resisting cataract. Also discovered is that dithiothreitol is the substance capable of effectively inhibiting denaturation by heat of crystallins such as beta B2. Accordingly, corresponding anti-cataract products can be prepared by selecting the target protein as the target point and using dithiothreitol and composition thereof as the raw materials. Cataract disease is an important pathogenic reason influencing the quality of life of Chinese people. The beta B2 is determined as the target protein with wide application, and provides the direction for the development of new drugs. The developed product is mainly used for prevention, and is used externally in combination. A novel drug resource is provided, and is the effective product for preventing, diagnosing and treating denaturation of crystallin or cataract and other related diseases, thereby generating remarkable social and economic benefits.

The invention relates to a drug for internal hemorrhoid, external hemorrhoid and mixed hemorrhoid treatment, with therapeutic effect to hemorrhoid bleeding, belonging to the field of Chinese patent medicine, comprising cordate houttuyia, purslane, liquirice, angelica, angelica sinensis, gentiana, astragalus, burnet, sophoricoside, plaster, Chinese rhubarb and Chinese honeylocust (or Chinese locust abnormal fruit), which is characterized that the drug can radically curing internal hemorrhoid, external hemorrhoid and mixed hermorrhoid; and the therapeutic effect greatly exceeds prior hemorrhoids drugs on the market according to a research on Chinese herbal medicine market for over thirty years. The drug has the advantages of world advanced radical therapeutic effect for hemorrhoids, safety and reliability, adequacy of drug resource, low cost and simple manufacturing technique, hopefully to be recognized soon.

The invention discloses a traditional Chinese medicine composition for treating stomachache. The traditional Chinese medicine composition is prepared from the following components in parts by weight through synthesis: nepenthes, sago cycas, radermachera sinica, stephania sinica Diels, fruit of michelia champaca, croton crassifolius, all-grass of winkled marshweed, cymbopogon citratus, cinnamomum camphora seeds, litsea cubeba root and fruits of osmanthus fragrans. All medicines are combined to achieve the effects of eliminating stasis to subdue swelling, promoting qi circulation to relieve pain, activating blood, invigorating the stomach, clearing heat, removing toxicity, dispelling the wind and expelling the cold. When being used for treating stomachache, the traditional Chinese medicine composition focuses on the pathological mechanism, treats both symptoms and root causes, has an obvious curative effect, low possibility of relapse is realized, and the healing duration is short. The traditional Chinese medicine composition is simplified in compatibility, wide in drug resource and low in cost.

The present invention relates to a traditional Chinese drug composition for treating chronic enteritis. The traditional Chinese drug composition is prepared from the following traditional Chinese drugs: baikal skullcap root, largehead atractylodes rhizome, submature bitter orange, Chinese pulsatilla, Chinese magnoliavine fruit, lightyellow sophora root, wrinkled gianthyssop herb leaf and chicken's gizzard-membrane. The traditional Chinese drug composition provided by the present invention has characteristics of simple preparing, low cost, wide drug resource, convenient use, good therapeutic effect, high cure rate, and no any toxic and side-effect.

The invention discloses a traditional Chinese medicine preparation for treating pediatric epilepsy. The traditional Chinese medicine preparation consists of the following raw materials in parts by weight: 3-9 parts of radix ligustici sinensis, 15-30 parts of elaeagnus angustifolia, 3-6 parts of ferula asafetida, 9-15 parts of rhizoma polygonati, 1.5-9 parts of liquorice, 9-27 parts of radix acanthopanacis semticosi, 6-15 parts of semen nelumbinis, 6-20 parts of mulberries, 6-15 parts of Chinese dates, 9-12 parts of hawthorns, 1-3 pats of stigma croci, 6-12 parts of lilium brownii and 5-10 parts of bombyx batryticatus. The invention further discloses a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation for treating pediatric epilepsy is a pure traditional Chinese medicine preparation which is remarkable in curative effect and free of obvious toxic and side effects, can be used for overcoming the problems of relatively high cost due to clinic application of drugs such as carbamazepine and zonisamide tablets at present and relatively large side effects to infant patients due to long-term application, and has the advantages of being quick in effect, definite in curative effect, wide in drug resource and low in cost.